一种新型10价肺炎球菌结合疫苗候选株在冈比亚成人、幼儿和婴儿中的安全性和免疫原性——一项1/2期随机双盲对照试验结果
在冈比亚开展的1/2期随机双盲对照试验中,34名未接种过肺炎球菌结合疫苗(PCV)的成人、112名曾接种PCV13的幼儿和200名未接种PCV的婴儿按1:1随机接受SIIPL-PCV或已上市对照疫苗。结果显示SIIPL-PCV耐受性良好,安全性可接受,对所有疫苗血清型均有免疫原性,支持开展3期非劣效性试验。
要点
- 婴儿中最常见征集性反应为注射部位压痛和发热,治疗组间无有意义差异。
- 未发生严重或重度疫苗相关不良事件,严重不良事件、疫苗相关不良事件或总体不良事件无有意义趋势。
- 除6A型(79%)外,SIIPL-PCV组婴儿初免后所有血清型血清应答率(IgG≥0.35 µg/mL)≥89%。
核心结论
- SIIPL-PCV耐受性良好,安全性可接受,对所有疫苗血清型均有免疫原性。
- 结果支持在3期非劣效性试验中评估SIIPL-PCV。
研究设计与样本
- 1/2期随机双盲对照试验在冈比亚序贯入组34名未接种过PCV的成人(18-40岁)、112名曾接种PCV13的幼儿(12-15月龄)和200名未接种PCV的婴儿(6-8周龄),按1:1随机接受SIIPL-PCV或已上市对照疫苗。
- 婴儿在6、10、14周龄接受三剂SIIPL-PCV或PCV13,与常规扩大免疫规划(EPI)疫苗同时接种;在96名婴儿亚组中评估10-14月龄时匹配加强剂的安全性和免疫原性。
主要发现
- 反应原性主要为轻至中度;婴儿中最常见征集性反应为注射部位压痛和发热,治疗组间无有意义差异。
- 未发生严重或重度疫苗相关不良事件,严重不良事件、疫苗相关不良事件或总体不良事件无有意义趋势。
- SIIPL-PCV组婴儿初免后血清应答率(IgG水平≥0.35 µg/mL)除6A型(79%)外所有血清型≥89%。
- SIIPL-PCV组和PCV13组所有血清型IgG几何平均浓度(GMC)均>1 µg/mL。
- 加强后GMC在组间相当。
关键数值与推荐
- 婴儿初免后血清应答率(IgG≥0.35 µg/mL):SIIPL-PCV组除6A型(79%)外所有血清型≥89%。
- SIIPL-PCV组和PCV13组所有血清型IgG GMC均>1 µg/mL。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A more affordable pneumococcal conjugate vaccine (PCV) that provides comparable protection to current PCVs is needed to ensure sustainable access in resource-limited settings. Serum Institute of India Pvt. Ltd.'s PCV candidate (SIIPL-PCV) has the potential to meet this need as manufacturing efficiency has been optimized and the vaccine targets the most prevalent disease-causing serotypes in Africa and Asia. We report SIIPL-PCV's safety, tolerability, and immunogenicity in adults, toddlers, and infants in The Gambia. METHODS: This phase 1/2, randomized, double-blind trial sequentially enrolled 34 PCV-naive adults (18-40 years old), 112 PCV (Prevenar 13® [PCV13])-primed toddlers (12-15 months old), and 200 PCV-naive infants (6-8 weeks old), who were randomized (1:1) to receive SIIPL-PCV or a licensed comparator vaccine. Infants received three-doses of SIIPL-PCV or PCV13 at 6, 10, and 14 weeks of age co-administered with routine Expanded Program on Immunization (EPI) vaccines. Reactogenicity was solicited through seven-days post-vaccination; unsolicited adverse events (AEs) were assessed throughout the study. The safety and immunogenicity of a matching booster at 10-14 months of age were evaluated in a subset of 96 infants. Immune responses were evaluated post-primary and pre- and post-booster vaccinations. RESULTS: Reactogenicity was primarily mild-to-moderate in severity. In infants, the most common solicited reactions were injection-site tenderness and fever, with no meaningful treatment-group differences. There were no serious or severe vaccine-related AEs and no meaningful trends in SAEs, vaccine-related AEs, or overall AEs. Infant post-primary seroresponse rates (IgG level ≥ 0.35 µg/mL) were ≥89% for all serotypes except 6A (79%) in the SIIPL-PCV group. IgG GMCs were >1 µg/mL for all serotypes in both SIIPL-PCV and PCV13 groups. Post-booster GMCs were comparable between groups. CONCLUSION: SIIPL-PCV was well-tolerated, had an acceptable safety profile, and was immunogenic for all vaccine serotypes. Results support the evaluation of SIIPL-PCV in a phase 3 non-inferiority trial. Clinicaltrials.gov: NCT02308540.
引用
- Clarke E, Bashorun AO, Okoye M, et al. Safety and immunogenicity of a novel 10-valent pneumococcal conjugate vaccine candidate in adults, toddlers, and infants in The Gambia-Results of a phase 1/2 randomized, double-blinded, controlled trial. Vaccine. 2019. PMID: 31843266. doi:10.1016/j.vaccine.2019.08.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。